HERTFORDSHIRE, England and
PITTSBURGH, Aug. 25, 2016 /PRNewswire/ -- Mylan N.V.
(NASDAQ, TASE: MYL) today announced it is taking immediate action
to further enhance access to EpiPen® (epinephrine
injection, USP) Auto-Injector by expanding already existing
programs in recognition of those patients who are facing the burden
of higher out-of-pocket costs. The company is reducing the patient
cost of EpiPen® Auto-Injector through the use of a
savings card which will cover up to $300 for their EpiPen 2-Pak®. For
patients who were previously paying the full amount of the
company's list price for EpiPen®, this effectively
reduces their out-of-pocket cost exposure by 50%. Mylan also is
doubling the eligibility for its patient assistance program, which
will eliminate out-of-pocket costs for uninsured and under-insured
patients and families as well.
Mylan CEO Heather Bresch said,
"We have been a long-term, committed partner to the allergy
community and are taking immediate action to help ensure that
everyone who needs an EpiPen® Auto-Injector gets one. We
recognize the significant burden on patients from continued, rising
insurance premiums and being forced increasingly to pay the full
list price for medicines at the pharmacy counter. Patients deserve
increased price transparency and affordable care, particularly as
the system shifts significant costs to them. However, price is only
one part of the problem that we are addressing with today's
actions. All involved must also take steps to help meaningfully
address the U.S. healthcare crisis, and we are committed to do our
part to drive change in collaboration with policymakers, payors,
patients and healthcare professionals."
Mylan has worked to help patients with commercial insurance pay
as little as $0 for
EpiPen® Auto-Injector using the My EpiPen Savings
Card®. In 2015, this resulted in nearly 80% of these
patients paying nothing out of pocket for their EpiPen®
Auto-Injector. However, as the health insurance environment has
evolved, driven by the implementation of the Affordable Care Act,
patients and families enrolled in high deductible health insurance
plans, who are uninsured, or who pay cash at the pharmacy, have
faced higher costs for their medicine.
Mylan is taking the following immediate actions to help further
address the needs of patients and families:
- For patients in health plans who face higher out-of-pocket
costs, the company is providing immediate relief by offering a
savings card for up to $300. This
will effectively reduce by 50% the cost exposure for patients who
would have otherwise paid the full list price for
EpiPen® Auto-Injector.
- Mylan also is doubling eligibility for our patient assistance
program to 400% of the federal poverty level. This means a family
of four making up to $97,200 would
pay nothing out of pocket for their EpiPen®
Auto-Injector.
- Further, Mylan will continue to offer the
EpiPen4Schools® program. The program, launched in
August 2012, has provided more than
700,000 free epinephrine auto-injectors and educational resources
to more than 65,000 schools nationwide to help them be prepared for
anaphylaxis events among students.
- Mylan also is opening a pathway so that patients can order
EpiPen® Auto-Injector directly from the company, thereby
reducing the cost.
These programs will apply to EpiPen® and
EpiPen Jr® (epinephrine injection, USP)
Auto-Injectors.
In the interest of fostering greater price transparency in the
healthcare system, Mylan is providing the entire economic story of
the EpiPen® supply chain on our website.
About EpiPen® (epinephrine injection, USP)
Auto-Injector
EpiPen® (epinephrine injection, USP) and
EpiPen Jr® (epinephrine injection, USP)
Auto-Injectors are used for the emergency treatment of
life-threatening allergic reactions. Each EpiPen
2-Pak® and EpiPen Jr
2-Pak® contains two single auto-injectors,
instructions for use and a training device, with no drug product or
needle, to help patients become familiar with the administration
technique. EpiPen® Auto-Injector should be
administered immediately at the first sign of an anaphylactic
reaction. EpiPen® Auto-Injector is not a
substitute for emergency medical treatment. Patients should
seek emergency medical attention immediately following
administration. For more information about
EpiPen® Auto-Injector, visit epipen.com.
About Mylan
Mylan is a global pharmaceutical company committed to setting
new standards in healthcare. Working together around the world to
provide 7 billion people access to high quality medicine, we
innovate to satisfy unmet needs; make reliability and service
excellence a habit; do what's right, not what's easy; and impact
the future through passionate global leadership. We offer a growing
portfolio of more than 2,700 generic and branded pharmaceuticals,
including antiretroviral therapies on which approximately 50% of
people being treated for HIV/AIDS in the developing world depend.
We market our products in more than 165 countries and territories.
Our global R&D and manufacturing platform includes more than 50
facilities, and we are one of the world's largest producers of
active pharmaceutical ingredients. Every member of our more than
40,000-strong workforce is dedicated to creating better health for
a better world, one person at a time. Learn more at mylan.com
Indications
EpiPen® (epinephrine injection, USP) 0.3 mg and
EpiPen Jr® (epinephrine injection, USP) 0.15 mg
Auto-Injectors are for the emergency treatment of life-threatening
allergic reactions (anaphylaxis) caused by allergens, exercise, or
unknown triggers; and for people who are at increased risk for
these reactions. EpiPen® and EpiPen Jr® are
intended for immediate administration as emergency supportive
therapy only. Seek immediate emergency medical help right away.
Important Safety Information
Use EpiPen® or EpiPen Jr® Auto-Injectors
right away when you have an allergic emergency (anaphylaxis).
Get emergency medical help right away. You may need further
medical attention. Only a healthcare professional should give
additional doses of epinephrine if you need more than two
injections for a single anaphylactic episode. EpiPen® or
EpiPen Jr® should only be injected into the
middle of your outer thigh (upper leg), through clothing if
necessary. Do not inject into your veins, buttocks, fingers, toes,
hands or feet. Hold the leg of young children firmly in place
before and during injection to prevent injuries. In case of
accidental injection, please seek immediate medical treatment.
Rarely, patients who have used EpiPen® or EpiPen
Jr® may develop an infection at the injection site
within a few days. Some of these infections can be serious. Call
your healthcare professional right away if you have any of the
following at an injection site: redness that does not go away,
swelling, tenderness, or the area feels warm to the touch.
Tell your healthcare professional about all of your medical
conditions, especially if you have asthma, a history of depression,
thyroid problems, Parkinson's disease, diabetes, high blood
pressure or heart problems, have any other medical conditions, are
pregnant or plan to become pregnant, or are breastfeeding or plan
to breastfeed. Be sure to also tell your healthcare professional
all the medicines you take, especially medicines for asthma. If
you have certain medical conditions, or take certain medicines,
your condition may get worse or you may have longer lasting side
effects when you use EpiPen® or EpiPen
Jr®.
Common side effects include fast, irregular or "pounding"
heartbeat, sweating, nausea or vomiting, breathing problems,
paleness, dizziness, weakness, shakiness, headache, feelings of
over excitement, nervousness or anxiety. These side effects usually
go away quickly if you lie down and rest. Tell your healthcare
professional if you have any side effect that bothers you or that
does not go away.
Please see the full Prescribing Information and Patient
Information.
You are encouraged to report negative side effects of
prescription drugs to the FDA.
Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
For additional information, please contact us at
800-395-3376.
EpiPen®, EpiPen Jr®, EpiPen
2-Pak®, EpiPen Jr 2-Pak®,
EpiPen4Schools® and My EpiPen Savings
Card® are registered trademarks owned by Mylan
Inc.
© 2016 Mylan Specialty L.P. All rights reserved.
Photo - http://photos.prnewswire.com/prnh/20160825/401225-INFO
Photo - http://photos.prnewswire.com/prnh/20160825/401226-INFO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/mylan-taking-immediate-action-to-further-enhance-access-to-epipen-epinephrine-injection-usp-auto-injector-300318188.html
SOURCE Mylan N.V.